Q BioMed Inc.
QBIO
$0.00
$0.000.00%
OTC PK
| 02/28/2023 | 11/30/2022 | 08/31/2022 | 05/31/2022 | 02/28/2022 | |
|---|---|---|---|---|---|
| Revenue | 209.30K | 284.40K | 376.80K | 396.20K | 270.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 209.30K | 284.40K | 376.80K | 396.20K | 270.70K |
| Cost of Revenue | 221.90K | 293.30K | 299.20K | 306.60K | 280.20K |
| Gross Profit | -12.70K | -9.10K | 77.40K | 89.50K | -9.60K |
| SG&A Expenses | 2.65M | 3.31M | 4.07M | 4.72M | 5.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.94M | 3.73M | 4.88M | 5.72M | 6.47M |
| Operating Income | -2.73M | -3.45M | -4.50M | -5.32M | -6.20M |
| Income Before Tax | -485.00K | -2.05M | -6.42M | -7.42M | -8.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.49 | -2.05 | -6.42 | -7.42 | -8.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -485.00K | -2.05M | -6.42M | -7.42M | -8.05M |
| EBIT | -2.73M | -3.45M | -4.50M | -5.32M | -6.20M |
| EBITDA | -2.68M | -3.40M | -4.45M | -5.27M | -6.15M |
| EPS Basic | -0.06 | -0.14 | -0.25 | -0.29 | -0.30 |
| Normalized Basic EPS | -0.02 | -0.05 | -0.12 | -0.15 | -0.17 |
| EPS Diluted | -0.07 | -0.14 | -0.25 | -0.29 | -0.31 |
| Normalized Diluted EPS | -0.02 | -0.05 | -0.12 | -0.15 | -0.17 |
| Average Basic Shares Outstanding | 258.03M | 178.89M | 135.99M | 118.75M | 112.03M |
| Average Diluted Shares Outstanding | 258.03M | 178.89M | 135.99M | 118.75M | 112.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |